With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC

2.

Virtual Reality Travel Reduces Cancer Pain.

3.

NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.

4.

Even a few mutated cells can significantly impact how blood cancers develop, study finds

5.

Omitting Biopsy After Negative MRI Halves Diagnoses of Insignificant Prostate Cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot